Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Sales & Earnings In Brief

This article was originally published in The Tan Sheet

Executive Summary

Advil sales help Wyeth: Worldwide net revenue increased by 10 percent to $5.8 billion for Madison, N.J.-based Wyeth's fourth quarter and 10 percent to $22.4 billion for its fiscal 2007, according to the firm's Jan. 30 earnings release. Worldwide consumer healthcare net revenue increased 10 percent for the October-December period and 8 percent for 2007, driven by Advilproducts and by Centrum, Caltrate andChapstick. Advilsales increased 8 percent to $186 million for the quarter and 10 percent to $684 million for the year; and Centrumsales showed a boost of 13 percent in the quarter to $204 million and 7 percent for the year, finishing at $705 million, according to the release. These results were offset by lower sales of Dimetapp and Robitussin due to a voluntary recall and replacement program the firm conducted in November (1"The Tan Sheet" Nov. 5, 2007, p. 8). For the year, Wyeth reported its diluted earnings per share increased 10 percent to $3.38. Wyeth is planning its own generic of its proton pump inhibitor Protonix (pantoprazole) to fend off competition, but says it has not considered switching the product to OTC. The firm says it is projecting workforce reductions of between 4 percent to 6 percent by the end of the first half of 2008...

You may also be interested in...

ENHANCE Results Do Little To Enhance Merck’s Statin Product Outlook

The Merck/Schering-Plough combination cholesterol therapy Vytorin has failed to demonstrate significant benefit over simvastatin alone in preventing formation of arterial plaque in the ENHANCE trial

Bristol-Myers Squibb Weighs Options On Mead Johnson

Bristol-Myers Squibb could reap as much as $10 billion by selling its Mead Johnson nutritional business and other non-pharmaceutical units, analysts say

Wyeth Replaces Dosing Measure For Pediatric Dimetapp, Robitussin Products

Wyeth Consumer Healthcare is voluntarily recalling and replacing Children's Dimetapp Cold & Chest Congestion and multiple products in its Robitussin line because the products' dosing cups are not marked with half-teaspoon units, the recommended dose for children ages 2 to 6, the firm said Oct. 29


Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts